As healthcare costs continue to reshape institutional balance sheets, pharmacy benefits have emerged as one of the most complex and rapidly expanding components of total compensation strategy. Employers, universities, and nonprofit systems are increasingly recognizing that benefit structures once treated as administrative functions now require governance-level oversight, particularly as new federal transparency legislation introduces stricter expectations around pricing visibility, rebate disclosure, and fiduciary accountability. Within this shift, a new partnership model is beginning to take shape, one grounded in fiduciary alignment, education, and long-term stewardship of financial resources.
AffirmedRx operates within the pharmacy benefit management (PBM) sector as a Public Benefit Corporation (PBC), supporting institutions in the design, administration, and financial governance of prescription drug programs. Rather than functioning solely as an intermediary between payers and pharmaceutical supply chains, the organization's model centers on transparency, data visibility, and institutional alignment. According to Greg Baker, CEO of AffirmedRx, the evolution underway reflects a broader rethinking of responsibility within healthcare ecosystems.
"Pharmacy benefits are no longer a back-office function," Baker explains. "They sit at the intersection of financial stewardship, patient access, and workforce wellbeing. Institutions are realizing that how these programs are structured directly affects their ability to fulfill their mission."
That realization is emerging alongside mounting economic pressure. Recent analysis projects medical cost trends to rise approximately 8.5% in 2026, driven in part by specialty pharmaceuticals and high-cost therapies. Complementing that outlook, research indicates that specialty medications accounted for roughly 50% of total pharmacy spend in 2021 despite representing a small share of overall prescriptions. Together, these forces are prompting institutional leaders to reexamine how pharmacy dollars are managed and governed.
From Baker's perspective, the response cannot be purely operational. He explains the future of benefit management as inherently relational. "The next era of healthcare partnerships will be defined by alignment," he says. "Organizations want partners who understand their fiduciary duty, not vendors focused on volume, but stewards focused on outcomes."
This distinction has given rise to what AffirmedRx calls Mission-Aligned Partnerships™. Within this initiative's framework, collaboration begins not with procurement but with education. Institutions are supported in understanding pricing structures, data flows, and clinical decision frameworks before evaluating program design.
John Dinkens has joined the AffirmedRx team as a senior consultant focused on institutional engagement, and he views this educational lens as foundational to sustainable reform. Drawing on decades of experience advising mission-driven organizations, he frames benefit governance through the same stewardship principles that guide philanthropic funding.
"When institutions raise or allocate resources, they do so with a responsibility to maximize the impact of each dollar," Dinkens explains. "Healthcare benefits should be viewed through that same fiduciary lens, how effectively dollars are being used to support people, access, and long-term wellbeing."
He notes that many institutional leaders are encountering pharmacy economics in depth for the first time. "Our role in mission-aligned dialogue is not to direct decisions," Dinkens says. "It is to ensure leaders are equipped with the right questions regarding transparency, incentives, and alignment, so they can determine what structure best serves their communities."
This shift from transactional procurement to consultative engagement reflects broader governance trends. Regulatory developments and federal transparency expectations are placing increased emphasis on reporting clarity, rebate visibility, and compensation disclosure. While policy evolution continues, the operational implication is already clear: institutions must now approach pharmacy benefits with the same diligence applied to other major financial systems.
Baker believes that the environment reinforces the value of partnership models built on openness rather than opacity. "Transparency is not a marketing phrase," he says. "It is an operational discipline. Institutions deserve clear insight into how decisions are made, how dollars flow, and how those decisions affect the people they serve."
Mission alignment also extends to patient experience. Baker notes that pharmacy navigation, adherence support, and access advocacy are becoming central components of benefit design as employers recognize the downstream impact of medication access on workforce health and productivity. He considers this a natural extension of institutional purpose. "When benefit strategy aligns with mission, it strengthens trust, not just financially, but culturally," he says. "Employees and stakeholders feel the difference when programs are built around care, clarity, and accountability."
Importantly, the Mission-Aligned Partnerships™ model does not presume uniform solutions. Educational dialogue often precedes structural change, and in some cases, institutions maintain existing arrangements while integrating new governance practices. Baker notes the emphasis is informed decision-making rather than prescriptive direction.
That philosophy reflects a larger redefinition of value within healthcare partnerships. Baker explains that as cost pressures intensify and data transparency expands, institutions are seeking collaborators capable of operating within both financial and human frameworks. "The nonprofit organizations we work with are stewards of communities, not just budgets," he says. "Our responsibility is to meet them at that level, with education, integrity, and alignment that extends beyond contracts."
Looking ahead, the trajectory of pharmacy benefit management appears increasingly tied to this relational architecture. Fiduciary accountability, data ownership, and patient advocacy are moving from differentiators to baseline expectations.
For Dinkens, the shift signals a maturation of the industry itself. "Mission-Aligned Partnerships™ invite institutions to think differently about benefits," he says. "Not as transactions to manage, but as strategic assets to steward responsibly. In this era of federal grantmaking changing rapidly, the need for innovation like this transformational initiative offers has never been greater."
As healthcare continues to evolve, that reframing may prove foundational, positioning education, transparency, and fiduciary trust not as supplementary values, but as the structural core of the next generation of healthcare benefit partnerships.
Baker summarized, "The bold vision for this initiative is modernized and personalized for the betterment of nonprofit organizations. As such, we are assembling our team of AffirmedRx stewards internally and externally to communicate our financial stewardship efforts widely."
Media Contact
Name: Sarah Forti
Email: sarah.forti@affirmedrx.com
